Seeking Alpha

Aimmune +11.6% on positive allergist survey

|About: Aimmune Therapeutics, Inc. (AIMT)|By: , SA News Editor

Piper Jaffray says a new proprietary allergist survey shows "massive upside" to sales potential and expectations for Aimmune's (NASDAQ:AIMT) peanut allergy drug.

Raymond James says the survey showed awareness and willingness to prescribe Palforzia.

Key quote: "While many have equated the opinions of a few high profile critics with the overall market view, bears would do well to pay attention to this feedback."

AIMT shares are up 11.6% after hours to $22.85.